Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy

C. Hézode, P. Kwo, J. Sperl, P. Hwang, J. Long, R. Talwani, MN. Robertson, BA. Haber,

. 2019 ; 11 (-) : 617-628. [pub] 20191120

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19043923

Introduction: Some direct-acting antiviral regimens for hepatitis C virus (HCV) infection pose safety or efficacy concerns if coadministered with drugs containing ethinyl estradiol. The present analysis was conducted to examine the impact of concomitant oral contraceptive pills (OCP) or hormone replacement therapy (HRT) during treatment with elbasvir (EBR)/grazoprevir (GZR) in women with HCV genotype (GT)1 or GT4 infection. Methods: This is a post hoc, integrated retrospective analysis of female participants with HCV GT1 or GT4 infection who received EBR 50 mg/GZR 100 mg once daily for 12 weeks in phase 2/3 clinical trials. The primary end point was sustained virologic response at 12 weeks after therapy completion (SVR12). For this analysis, participants were stratified according to whether they received OCP or HRT during the original treatment study. Results: A total of 1,022 women with HCV GT1 or GT4 infection were included (receiving OCP/HRT, n=81; not receiving OCP/HRT, n=941). Most participants receiving OCP/HRT were treatment-naive (79%), noncirrhotic (91.4%), and aged >35 years (71.6%). SVR12 rates were similar in women receiving OCP/HRT and those not receiving OCP/HRT (95.1% vs 96.3%). SVR12 rates remained high across all subgroups within the population receiving OCP/HRT: SVR12 rates were 94.6%, 100%, and 100% in participants with GT1a, GT1b, and GT4 infection, and all women aged 18-35 years achieved SVR (21/21). Treatment-related adverse events occurred in 40.7% (33/81) and 30.1% (283/941) of women receiving and those not receiving OCP/HRT, respectively. Conclusion: The efficacy and safety of EBR/GZR administered for 12 weeks was similar in women receiving OCP/HRT and those not on OCP/HRT. These data indicate that EBR/GZR can be safely used for the treatment of HCV GT1 or GT4 infection in women receiving concomitant OCP/HRT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19043923
003      
CZ-PrNML
005      
20200109095118.0
007      
ta
008      
200107s2019 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/IJWH.S203022 $2 doi
035    __
$a (PubMed)31819666
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Hézode, Christophe $u Service d'Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France.
245    10
$a Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy / $c C. Hézode, P. Kwo, J. Sperl, P. Hwang, J. Long, R. Talwani, MN. Robertson, BA. Haber,
520    9_
$a Introduction: Some direct-acting antiviral regimens for hepatitis C virus (HCV) infection pose safety or efficacy concerns if coadministered with drugs containing ethinyl estradiol. The present analysis was conducted to examine the impact of concomitant oral contraceptive pills (OCP) or hormone replacement therapy (HRT) during treatment with elbasvir (EBR)/grazoprevir (GZR) in women with HCV genotype (GT)1 or GT4 infection. Methods: This is a post hoc, integrated retrospective analysis of female participants with HCV GT1 or GT4 infection who received EBR 50 mg/GZR 100 mg once daily for 12 weeks in phase 2/3 clinical trials. The primary end point was sustained virologic response at 12 weeks after therapy completion (SVR12). For this analysis, participants were stratified according to whether they received OCP or HRT during the original treatment study. Results: A total of 1,022 women with HCV GT1 or GT4 infection were included (receiving OCP/HRT, n=81; not receiving OCP/HRT, n=941). Most participants receiving OCP/HRT were treatment-naive (79%), noncirrhotic (91.4%), and aged >35 years (71.6%). SVR12 rates were similar in women receiving OCP/HRT and those not receiving OCP/HRT (95.1% vs 96.3%). SVR12 rates remained high across all subgroups within the population receiving OCP/HRT: SVR12 rates were 94.6%, 100%, and 100% in participants with GT1a, GT1b, and GT4 infection, and all women aged 18-35 years achieved SVR (21/21). Treatment-related adverse events occurred in 40.7% (33/81) and 30.1% (283/941) of women receiving and those not receiving OCP/HRT, respectively. Conclusion: The efficacy and safety of EBR/GZR administered for 12 weeks was similar in women receiving OCP/HRT and those not on OCP/HRT. These data indicate that EBR/GZR can be safely used for the treatment of HCV GT1 or GT4 infection in women receiving concomitant OCP/HRT.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kwo, Paul $u Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
700    1_
$a Sperl, Jan $u Department of Hepatogastroenterology, Institut Klinické a Experimentální Medicíny (IKEM), Prague, Czech Republic.
700    1_
$a Hwang, Peggy $u Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA.
700    1_
$a Long, Jianmin $u Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA.
700    1_
$a Talwani, Rohit $u Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA.
700    1_
$a Robertson, Michael N $u Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA.
700    1_
$a Haber, Barbara A $u Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA.
773    0_
$w MED00176305 $t International journal of women's health $x 1179-1411 $g Roč. 11, č. - (2019), s. 617-628
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31819666 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200107 $b ABA008
991    __
$a 20200109095447 $b ABA008
999    __
$a ind $b bmc $g 1480512 $s 1082593
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 11 $c - $d 617-628 $e 20191120 $i 1179-1411 $m International journal of women's health $n Int. j. women's health $x MED00176305
LZP    __
$a Pubmed-20200107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace